ONCAlert | 2018 ASCO Annual Meeting

Effect of Age and Lenvatinib Treatment on OS for Patients With Thyroid Cancer

Lori J. Wirth, MD
Published Online: 6:28 PM, Thu June 4, 2015

Lori J. Wirth, MD, hematology/oncology, Department of Medicine, Massachusetts General Hospital, discusses the SELECT trial, which examined the effect of age and lenvatinib treatment on overall survival (OS) for patients with 131I-refractory differentiated thyroid cancer.
<<< View more from the 2015 ASCO Annual Meeting

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.